ENGlobal, a leading provider of engineering and automation services, today reported its financial results for the second quarter ended June 27, 2015.

Second quarter 2015 revenues totaled $21.1 million, a $6.1 million decrease from $27.2 million reported for the prior year period. Net income totaled $1 million, or $0.03 per diluted share, for the quarter ended June 27, 2015, compared to net income of $1.6 million, or $0.06 per diluted share, for the quarter ended June 28, 2014. During the quarter ended June 27, 2015, the company incurred non-cash expenses for depreciation, amortization and stock compensation of $0.5 million as compared to $0.7 million for the same period in 2014.

Mark Hess, ENGlobal’s Chief Financial Officer, stated, “We are pleased to report today’s profitable results—which I’m proud to say represents six consecutive profitable quarters. ENGlobal’s profit margins remain respectable given the current environment, and our available capital has improved over the last year. The Company continues to maintain a healthy cash balance and working capital of $25.4 million, and we have no borrowings under our current credit facility.”

“ENGlobal’s response to the current energy marketplace has been to increase our efforts in developing new business,” added William Coskey, P.E., Chairman and Chief Executive Officer of ENGlobal. “While we are excited about several new opportunities and client relationships that this internal process has produced, it also appears to be a great time to consider strategic acquisitions.”

For more information on ENGlobal, visit www.englobal.com

Cumberland Pharmaceuticals is a specialty pharmaceutical company focused on the acquisition, development and commercialization of branded prescription products. The company’s product portfolio currently features five marketed treatments – including Acetadote®, Caldolor®, Kristalose®, Vaprisol® and Omeclamox-Pak® – addressing its primary target markets of hospital acute care and gastroenterology. Cumberland owns the worldwide rights to all of its brands, allowing the company to focus on the U.S. market while actively pursuing strategic partnerships and other opportunities to make its products available to patients in underserved international markets.

In the second quarter of 2015, Cumberland’s strongest performing product was Kristalose, which accounted for $4.1 million in net revenue. As the only branded prescription laxative product that features the established safety and efficacy of lactulose in a pre-measured powder dose, Kristalose offers patients a virtually tasteless, grit-free and essentially calorie-free alternative to lactulose syrups. In a 2009 study by Clinical and Experimental Gastroenterology, the company’s product was preferred by 83 percent of patients, highlighting the immense market potential of Cumberland’s product portfolio moving forward.

In addition to its commercialized products, Cumberland is currently engaged in late-stage clinical development of two promising drug candidates. Hepatoren® is being developed to treat patients suffering from hepatorenal syndrome, while Boxaban® is being developed for the treatment of aspirin-exacerbated respiratory disease. Enrollment for phase II studies of both candidates is underway and expected to be completed by the end of 2015. To ensure reliable expansion of its product portfolio in the future, Cumberland also operates Cumberland Emerging Technologies (CET), which, in collaboration with some of the country’s top universities, is providing the company with a long-term pipeline of new product candidates.

As of June 30, 2015, Cumberland reported approximately $93 million in total assets, including $53 million in cash and investments, with only $14.2 million in total liabilities. In the coming months, the company will look to leverage the flexibility offered by this balance sheet to promote long-term, sustainable growth.

“We remain in a strong financial position with a solid balance sheet and profitable operations,” A.J. Kazimi, chief executive officer of Cumberland, stated in a news release. “We are working to maximize the potential of our five commercial products and actively pursuing the addition of new brands to our portfolio.”

With an established product portfolio, a promising development pipeline and a steady supply of new candidates provided by CET, Cumberland is in a strong strategic position to expand upon its considerable industry presence in the years to come. For prospective shareholders, the company’s favorable balance sheet and persistent commitment to expanding upon its market share could foreshadow an opportunity for Cumberland to achieve sustainable returns for the foreseeable future.

For more information, visit www.cumberlandpharma.com

An estimated two billion people around the globe want to learn to speak English, providing a significant opportunity for businesses that can translate this market demand into financial returns. In 2013, the global market for language learning was estimated at more than $56 billion, and English programs accounted for a substantial portion of that spending. Lingo Media Corporation (OTCQB: LMDCF), through a combination of both online and print-based education products, is thriving in this lucrative market segment under the leadership of one of the industry’s most seasoned executive teams.

For many years, Lingo’s operations centered on a business unit that co-publishes textbook programs used in China. In 2014, this established unit reported free cash flow of about $1.5 million. However, in recent months, the company has transitioned its operations to take advantage of the rapidly expanding market for educational technology, which is currently outpacing the growth of brick-and-mortar education by a considerable margin. As a result, Lingo promptly acquired an award-winning content library, as well as two other eLearning platforms, to create one of the most diverse, customizable language learning tools on the market.

Through its proprietary eLearning software, Lingo adds a collection of revenue streams that capitalize on the strong performance of the global language-learning market. In particular, the company receives licensing fees for each new client, as well as recurring licensing fees throughout the educational experience. By partnering with a top-tier software development team, Lingo has successfully built a library that boasts thousands of lessons designed to meet the specific needs of its clients, improving the outlook of licensing revenue for the foreseeable future.

When entering new markets, Lingo utilizes an innovative business strategy to keep costs down without sacrificing on client satisfaction. Instead of opening permanent offices in each individual country, the company forms relationships with external contractors and distributors in order to market its products. This strategy allows Lingo to consistently minimize costs, giving the company an advantage over its competitors in the same markets. For prospective shareholders, these efforts promote high margins and potentially rapid growth.

In the first quarter of 2015, Lingo demonstrated the effectiveness of its unique approach to market growth by posting a 176 percent year-over-year increase in revenue, recording over $651,000 for the period. Similarly, the company recorded a net profit of more than $225,000, up from a net loss of $52,870 in the same period of the previous year. Lingo will look to build on this profitability throughout the remainder of 2015.

Moving forward, Lingo’s priority is to win new contracts and fuel revenue, earnings and cash flow in an attempt to pay off outstanding debt and finish the year with a clean balance sheet. Since small-cap growth stocks with low debt and high profit margins offer strong potential for market gains, these efforts could serve as a catalyst for rapid increases to Lingo’s market value in the months to come.

For more information, visit www.lingomedia.com

QualityStocks today announces the availability of a new audio interview with Mr. Eric Fresh, Senior Vice President of Finance and Investments for Dominovas Energy Corporation (OTCQB: DNRG). The interview can be heard at www.QualityStocks.net/interview-dnrg.php.

At the forefront of Dominovas Energy’s mission to deliver clean, efficient and reliable electricity to areas of the world that lack this valuable commodity is the Company’s proprietary technology, the RUBICON™, and its visionary leadership. Fresh begins the interview by discussing his own expertise, how it applies to the Company’s vision, and why he believes Dominovas Energy is positioned for success.

“What brought me to Dominovas Energy initially was the opportunity to work with an extraordinary executive suite. The Company’s vision to deploy its RUBICON™ system globally was indeed exceptional… I’ve worked on more than $4 billion of structured debt and equity transactions for projects all over the world. Most of those were directly related to power generation in the energy sector. Dominovas Energy, as a company, is poised and positioned for unprecedented success in the global power sector,” asserted Fresh.

Dominovas Energy is the first and only fuel cell company selected as a private sector partner to President Barack Obama’s Power Africa Initiative (PAI). Fresh describes how the Company’s partnership with Delphi Automotive Systems validates a robust supply chain in the manufacture of its solid oxide fuel cell stacks, which is the heart of the RUBICON™ system, and how its deployment fits into the broader value created to impact both domestic and foreign economies.

“Collectively, with our OEM partners, we have a significant, vested interest in the successful deployment of our RUBICON™ systems throughout sub-Saharan Africa… consider the relationship with our U.S.-based OEM partner Delphi Automotive Systems. Our relationship presents a broad-based value proposition. The engagement of Delphi secures the Company’s supply chain relative to its most critical component: the production of fuel cell stacks. This partnership affords Dominovas Energy a capability well beyond any other fuel cell company in the market,” he explains.

As further mentioned in the interview, Dominovas Energy has signed more than 200MW of guaranteed PPAs, establishing the base of production that promotes “efficient and cost-effective” manufacturing of the Company’s proprietary RUBICON™ system. Fresh notes that ongoing production and manufacturing of the system will create a hearty global supply chain and stimulate global job expansion while supporting the PAI to create greater access to electricity in sub-Saharan Africa.

Fresh also eased concerns regarding how U.S. Export Import Bank’s charter not being re-authorized impacts the financing of RUBICON™’s deployment.

“We see no immediate impact as the Company has not to date initiated any financing sequences with them. However, it is indeed unfortunate that the U.S. Ex-Im Bank’s charter has not been reauthorized, as Ex-Im has been, and is, a critical component of many U.S. companies that are engaged in international commerce.”

Dominovas Energy is however actively engaging several Power Africa Partners, both private and public, that are steadfast in their commitment relative to financing project development and deployment of RUBICON™ systems in sub-Saharan Africa. These Initiative Partners include Goldman Sachs, Barclays Africa, the Overseas Private Investment Corporation (OPIC) and Africa Development Bank (AfDB).

“Ultimately, each of the institutions that we engage are engaged specifically because they have mandates which are inclusive of being focused on deploying capital to support further development of power infrastructure projects in sub-Saharan Africa,” says Fresh.

Turning to expenses associated with deployment, Fresh provides an account of the variables that affect the costs to install power generation based upon the RUBICON™.

“The RUBICON™ is a precision engineered and highly customized next-generation technology that produces clean, reliable and sustainable electricity in global emerging markets… many of these markets lack the infrastructure for basic access to electricity, so our customizable, modular, megawatt-scaled RUBICON™ units are ideal, as there’s no reliance on antiquated legacy transmission infrastructure,” reminds Fresh.

Fresh concludes the interview by addressing what some would perceive as challenges to obtaining financing of projects in the Democratic Republic of Congo (DRC), and how the company is providing an unprecedented number of megawatts.

“Financing such a large deployment is not as much a challenge, as it is a spectacular opportunity for Dominovas Energy. The DRC is a country rich with potential. It is indeed that potential that presents an unprecedented opportunity for Dominovas Energy. Through years of cultivating relationships at the highest levels in government, we are now realizing the fruits of that labor with the prospect of adding to those resources, in a very significant way; mind you, by delivering power with attendant financial support,” says Fresh. “The Company is continually enhancing and cultivating its financial relationships along with its ability to execute in the DRC.”

Again, the interview can be heard at http://www.QualityStocks.net/interview-dnrg.php.

Let us hear your thoughts: Dominovas Energy Corp. Message Boards

FluoroPharma Medical is a biopharmaceutical company engaged in the discovery and development of proprietary positron emission tomography (PET) imaging agents for the efficient detection and assessment of acute and chronic forms of coronary artery disease (CAD). Currently, the company is advancing two such product candidates in clinical trials – including CardioPET and BFPet – which have been specially designed to rapidly target myocardial cells. Upon commercialization, these innovative products are expected to enable more accurate, early diagnosis of CAD, effectively facilitating improved treatment options and better patient outcomes.

The market potential for a more effective diagnostic tool for CAD is expansive. According to a report by the Centers for Disease Control and Prevention, heart disease accounts for approximately 610,000 deaths in the United States each year, making it the country’s leading cause of death. Among these fatalities, approximately 47 percent occur as a result of heart attacks outside of hospitals, suggesting that many people with CAD don’t receive proper diagnosis. FluoroPharma is addressing this issue by developing molecular imaging as a faster, more accurate approach to today’s standard test for diagnosing CAD.

CardioPET is designed to address the current limitations of CAD diagnostics. Upon commercialization, CardioPET is expected to be the first commercially-available fatty acid analog marker in the U.S. and Europe, giving FluoroPharma a noteworthy strategic advantage in the substantial diagnostic markets of the two regions. Unlike currently available tools, a traceable fatty acid analog marker will enable improved evaluation of cardiac blood flow and the dietary preference of the cardiac muscle under stress and at rest, clearly indicating the metabolic state of the heart and providing a more comprehensive assessment of CAD.

“We are encouraged by our progress to date, and believe that CardioPET potentially signals a compelling new direction for PET cardiac imaging at a time when healthcare professionals around the world could benefit from novel diagnostic imaging that expand and improve their diagnostic capabilities,” Thijs Spoor, chairman and chief executive officer of FluoroPharma, stated in a news release.

According to its most recent update, the company has completed enrollment for its phase II clinical trial of CardioPET for the assessment of CAD. This study, which is designed to assess the safety and diagnostic performance of FluoroPharma’s innovative agent, marks a significant step in the continued development of CardioPET. For prospective shareholders, the company’s sustained progress toward the commercialization of its promising development pipeline, in addition to the considerable marketability of its proprietary diagnostic tools, could foreshadow an opportunity for FluoroPharma to achieve sustainable returns in the months to come.

For more information, visit www.fluoropharma.com

With the success of its nine-month GLP safety (tumorigenicity) and biodistribution animal model study in Parkinson’s Disease (PD) showing a completely clean record, as zero tumor growth was observed across a batch of 300 rodents injected with the company’s ethically and proprietarily-derived human neural stem cells (hpNSCs), International Stem Cell Corp. has subsequently taken a major step to increase the company’s market presence and up-list to a major exchange, announcing a reverse stock split in order to tighten the overall share structure. Since the July 29 split announcement, the company’s ticker has been ISCOD, and it will remain so until the typical period of approximately 20 days has elapsed.

The recently completed nine month GLP safety study, which capitalizes on a long track record of successfully demonstrated results stretching back to such examples as the 2013 work with Duke University’s Clinical Research Institute, was the last step needed for International Stem Cell to secure the previously announced landmark phase 1/2a clinical trial in PD with the Australian Therapeutic Goods Administration via the company’s recently-formed Australian subsidiary, Cyto Therapeutics Pty Ltd. The company has quite a preclinical dataset to back up its novel approach to treating PD with injected hpNSCs, which are self-renewing multipotent precursor cells to the main types of cells that make up the CNS (central nervous system), created using the company’s proprietary parthenogenetic technology, which chemically differentiates unfertilized human eggs (oocytes) into pluripotent stem cells (capable of giving rise to many different cell types).

This extensive preclinical dataset the company has thus far amassed, showing zero evidence of tumor formation at even high dosages (including proof-of-principle PD cohort studies and additional studies focused on safety), combined with direct evidence that injected hpNSCs exhibit a neuroprotectant capacity, as well as an ability to actively recover neurons and address the core motor function symptomatology of PD characterized by dopamine deficiency, is an extremely positive forward indicator to investors. International Stem Cell Corporation has been steamrollering forward with incredible momentum in 2015, ever since the announcement in December of last year that the EU’s Court of Justice ruled in favor of the company’s core technology patent applications, declaring them to be effectively outside the scope of prohibitions on patenting embryonic stem cells, due to a laser-like focus on only ethical derivation of non-embryonic stem cells from unfertilized eggs. Ethically-derived sourcing is a key advantage for International Stem Cell Corporation, especially in the current environment, where a political and ethical debate about stem cell technology is heating up.

Highlights for the company so far this year include solid Q1 results reported in March, showing a 74 percent uptick in gross margins on the strength of a 76 percent increase in operating income from the company’s cosmeceutical and biomedical commercialization. Income growth to $1.62 million in revenue was led by a 5 percent sales jump at the company’s Lifeline Skin Care subsidiary, which specializes in providing rejuvenating skin care products based on nanosphere-enscapsulated proteins extracted from parthenogenetic stem cells. Additionally, the company made waves in the regenerative therapy industry with a talk given in May at the International Society for Cellular Therapy’s (ISCT) annual meeting by the company’s CSO, Ruslan Semechkin, Ph.D., highlighting the potential of hpNSCs for treating PD. The ISCT is the leading global association focused on innovative preclinical and translational cell therapy product development, and Dr. Semechkin’s talk on hpNSC therapy left a lasting impression on key industry participants who attended the Regeneration and Nervous System Repair session at the organization’s 21st annual meeting in Las Vegas.

This move to reverse split the common stock and up-list to a major exchange comes at an auspicious time for International Stem Cell Corporation as the company rockets towards commercialization of a potentially genuine treatment option for PD sufferers and their families. With GlobalData estimates on the PD treatment market running into the $5.3 billion range within the next seven years alone, growing at a compound annual rate of over four percent, International Stem Cell Corporation is poised to become one of the big names in PD treatment, especially considering the company’s ample IP position. The company has made a herculean effort thus far to globally secure its core technology, as well as specific pluripotent human parthenogenetic stem cell (hpSC) lines, with 16 issued patents and 91 pending applications spanning 15 patent families, as well as eight more pending applications across four other patent families related specifically to skin care products. International Stem Cell Corporation has even licensed an additional portfolio of 11 issued and 14 pending patents/applications covering eight patent families in order to further secure its broad-spectrum and rapidly developing hpSC treatment pipeline.

This pipeline includes developing the same hpNSCs used to treat PD, in order to provide stroke patients with the first real solution to this leading cause of adult disability, and the company already has robust preclinical evidence that injection of these highly-pure hpNSCs can be used to actually reverse functional deficits when applied even several weeks after the initial event. This one development would be a major commercial victory for the company and it would also largely establish the concrete viability of its parthenogenetic technology for creating commercial-scale, implant-ready cell banks for the ischemic (roughly 87 percent of cases) stroke treatment and other markets. Not to mention being a game-changer for the roughly 691,650 people every year in the U.S. who suffer from ischemic strokes. People whose only current option is costly, laborious, logistically difficult to implement, and often ineffective cognitive/functional rehabilitation. Commercial success in either PD or ischemic stroke would roundly validate the company’s underlying therapeutic approach for treating other diseases and disorders as well, potentially opening a floodgate for the company and allowing them the kind of financial muscle and industry clout needed to knock down additional targets with hpSC-based therapies.

The company’s hpSC technology is currently being developed for areas such as age-related macular degeneration via parthenogenetically-derived human retinal epithelium (RPE) cell therapy, as well as for corneal blindness and many other eye diseases/disorders via the production of corneal cells and whole corneal tissue. This same technology also shows great promise for treating metabolic (and other types of) liver diseases, such as Crigler-Najjar syndrome (inherited), and the company has already successfully created and characterized stem cell-derived liver cells under its CytoHep program, whose transplantation has been shown to effectively delimit the brain and nerve damage associated with Crigler-Najjar syndrome in preclinical animal models.

If one observes all of these emerging hpSC treatment vectors from a wide angle, it becomes strikingly apparent that we could potentially be treating a whole host of degenerative and other diseases/disorders with 100 percent ethically derived stem cell technology. International Stem Cell Corporation is at the forefront of this industry and the shoring-up of its share structure in anticipation of up-listing to a major exchange, in conjunction with the upcoming landmark clinical trials in PD, for which the company has already comfortably sustained the cost on and manufactured a cell bank of over 2.6 billion high-purity hpNSCs (enough to satisfy all foreseeable clinical trial needs), is an extremely bullish indicator to the investment community about where the company is heading.

Continued success of the company’s already commercialized cosmeceutical and biomedical product operations forms a key backdrop for International Stem Cell Corporation when it comes to funding ongoing clinical and preclinical efforts, further differentiating the company (alongside its strong IP position) from competitors.

Take a closer look by visiting www.internationalstemcell.com

Let us hear your thoughts: International Stem Cell Corp. Message Board

America Resources Exploration is an oil and gas exploration and production company focused on the acquisition of properties in areas with significant oil reserves. Currently, the company holds a collection of leaseholds in promising production areas around the country – including parts of Oklahoma, Texas and Utah. By diversifying its interests and remaining flexible, AREN is able to maintain steady production levels that ensure operational consistency, even in less-than-favorable market conditions.

In recent months, AREN has made considerable progress toward expanding its market share in the domestic oil and gas industries. Despite slumping commodity prices that continue to hamper industry growth, the company has acquired a collection of production assets in its current operating regions, dramatically strengthening its strategic positioning in some of the country’s most prolific oil production areas. Most recently, AREN announced its acquisition of a fractional interest in 56 oil and gas wells located in Oklahoma.

The company’s commitment to expanding upon its portfolio of production assets is a long-term tactic that leverages the benefits of the current lower commodity price environment. In particular, AREN’s growth strategy centers on the acquisition of oil fields from distressed third parties at a substantial discount to value. When oil and gas prices recover, these efforts are expected to place AREN into a strengthened position to increase its production levels in a financially-viable manner, effectively promoting improved cash flow and increased value for the company’s shareholders.

AREN is committed to becoming a world leader in hydrocarbons production, requiring the company to continuously achieve superior financial and operational results while simultaneously adhering to high ethical standards. Moving forward, the company will continue to lean on the exceptional quality of its workforce in order to attain a competitive edge in the oil and gas industry. This advantage, when combined with disciplined and selective evaluation of capital investment opportunities, will serve as the foundation for AREN’s pursuit of its goal of achieving record revenues for the 2015 calendar year.

For more information, visit www.america-resources.com

Recent strides toward sustainable market growth through the Power Africa Initiative have investors of Dominovas Energy Corp. (OTCQB: DNRG) excited for what the months to come may hold. On Monday, the company built upon this excitement when it announced a private placement that’s expected to provide up to $10 million of funding to serve as working capital throughout this period of expansion. While its proprietary RUBICON™ solid oxide fuel cell system certainly has a major part to play in the company’s recent success, Dominovas’s experienced management team has been the guiding force behind its current strategic positioning.

The Dominovas leadership team, along with its manufacturing partners, possesses over 200 years of combined business experience at the executive level. Benefitting from first-hand experience with engineering, supply chain management, marketing, legal and construction management, Dominovas has burst onto the scene since being acquired by Western Standard Energy Corp. in early 2014. In particular, the company’s historic partnership with the United States government, making it the only private sector partner to the Power Africa Initiative, highlights the market potential provided by a well-seasoned team of executives.

Leading the company’s management team is Neal Allen – chairman, president and chief executive officer of Dominovas. Allen brings a host of management experience to the company, having previously served as the principal shareholder of a private family office with a collection of diversified endeavors. Also on the Dominovas management team is Dr. Shamiul Islam, serving as the executive vice president of fuel cell operations. Islam is noted as one of the world’s foremost experts on solid oxide fuel cell technology, and he possesses a collection of patents applicable to fields related to the company’s proprietary technology.

In addition to its management, the Dominovas leadership team includes four key team members operating in the company’s primary international markets. Emilio DeJesus is a member of this team, serving as the president of Dominovas Energy AFRICA. In this position, DeJesus provides pertinent intelligence regarding the barriers of entry and political climate of African nations, as well as locating suitable business partners. In recent weeks, he has played an integral role in the development of the company’s RUBICON deployment plan for the sizable Power Africa Initiative.

Bringing together a strong strategic position in an expansive energy market with an experienced and well-rounded leadership team, Dominovas is primed to achieve strong financial growth for the foreseeable future. For prospective shareholders, the company’s promising outlook makes it an intriguing investment opportunity moving forward.

For more information, visit www.dominovasenergy.com

Let us hear your thoughts: Dominovas Energy Corp. Message Boards

Texas-based Galenfeha is an engineering and product development company constantly researching new technologies to ensure their clients are always on the leading edge. The company considers this technology leadership approach critical to their industrial position and the future of their customers. One of the most important aspects in this forward-thinking orientation is their environmental awareness, which they feel will continue to grow in importance as a mark of responsible business, and will help drive and ensure success.

Galenfeha doesn’t just grab business. The company evaluates each new project carefully, on a case-by-case basis, to be certain that it meshes with their overall mission, while being in the best interest of shareholder partners and responsible business. To this end, Galenfeha offers uniquely efficient and innovative products.

Their DLP-S Solar Powered Chemical Injection Pump was engineered to offer high reliability, simplicity in operation, and efficiency in serviceability. It is built from the highest grade 316 SS, and is able to withstand the harshest environments. The multi-purpose pump is available in a range of configurations, and can be custom matched to specific applications.

The DLP-P Pneumatic Chemical Injection Pump is unique in combining the rate precision of a solar powered digital control system and the reliability of a pneumatic pump. Together, it brings both ruggedness and reliability to the forefront of chemical injection technology.

iWAV is a system that enables complete control of your entire chemical injection program, offering maximum returns on one of the single highest costs involved in operating a well site. Whether communication is radio, cellular, satellite, or direct, the iWAV is ready to meet the needs of any size operation.

In the stored energy area, Galenfeha’s Lithium iron Phosphate (LiFePO4) is the ideal light weight replacement for the lead-acid battery, and will require no change to existing systems. It eliminates the solar regulator and can decrease the size of solar panels.

For more information on the company, visit www.galenfeha.com

Let us hear your thoughts: Galenfeha, Inc. Message Board

Latitude 360 is an award-winning pioneer of a dining and entertainment venues that combine premier upscale casual dining with numerous state-of-the-art entertainment choices. The company develops, constructs and operates cutting-edge Latitude 360 venues ranging from 35,000-85,000 sq. ft., packed full of eating and entertainment options that appeal to a broad base of guests, private events and corporate clients.

Through its three current award-winning locations in Jacksonville, Florida, Pittsburgh, Pennsylvania, and Indianapolis, Indiana, Latitude 360 employs roughly 500 talented individuals working to deliver the brand’s unique “360 EXPERIENCE” which fuses the magic of exceptional food and beverage with multiple entertainment options in upscale, contemporary-designed venues. Key offerings at each 360 location include Las Vegas-style live performance showroom, a feature bar featuring the area’s top musicians and/or DJs, luxury bowling, dine-in movies, high-definition sports theatre, game arcade and luxury cigar lounge and many choices of private meeting space.

In 2014 Latitude 360 launched the first-of-its-kind monthly club membership program which provides guests with a cache of monthly entertainment assets at a value price as well as exclusive access to a 360 Club Concierge service – all for a monthly fee. The program has quickly grown to more than 5,000 monthly paying members.

Latitude 360 recently expanded its entertainment offerings when it acquired Major League Fantasy (MLF), a leader in the daily fantasy sports industry. By implementing “360 Fantasy Live” into is existing locations, Latitude 360 is making a strong entrance into a rapidly growing market expected to reach $6 billion-$10 billion by year-end 2016. The acquisition of MLF allows Latitude 360 to position itself as one of the first live, multimedia venues to offer in-house, high-stakes, competitive daily fantasy events.

Led by an experienced and visionary management team, Latitude 360 is focused on further expanding its brick and mortar locations and anticipates opening additional 360 venues overseas and domestically in major cities like New York, Boston, Atlantic City and Chicago.

Let us hear your thoughts: Latitude 360, Inc. Message Board